<DOC>
	<DOCNO>NCT01761578</DOCNO>
	<brief_summary>This prospective , multicentre , open label , single arm , first man interventional investigation aim evaluate safety ART18Z bioresorbable stent treatment patient single de novo lesion native coronary artery mandatory balloon predilatation .</brief_summary>
	<brief_title>ARTDIVA Study : First Man Safety Evaluation ART18Z Bioresorbable Stent</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Eligibility : Healthy voluntary woman childbearing potential accepted Angiographic Target lesion must meet follow criterion Single vessel lesion De novo lesion Located native coronary artery visually estimate nominal artery diameter 2.8 3.2 mm Length ≤ 8 mm visually estimate Located major artery branch visually estimate stenosis &gt; 50 % &lt; 100 % TIMI flow ≥1 General Patient profile : Patient able verbally confirm understand risk , benefit treatment alternative receive ART18Z Bioresorbable Stent . Patient provide write informed consent approve EC prior clinical investigation related procedure Patient must agree undergo clinical investigation plan require clinical followup visit , QCA , OCT Patient must agree participate clinical investigation period 3 year follow procedure social security number require , otherwise patient include trial . Clinical profile : Silent ischemia , stable unstable angina document ischemia ( stress echocardiography , 12lead ECG , nuclear imaging , bicycle test , Treadmill stress test ) 3 month limited clopidogrel treatment must acceptable compliance patient health status Patient must acceptable candidate coronary artery bypass graft ( CABG ) surgery Angiographic Target lesion meet follow criterion : Aortoostial location ( within 3 mm ) Left main location locate within 3 mm origin LAD LCX Located within arterial saphenous vein graft distal diseased ( defined vessel irregularity per angiogram &gt; 20 % stenosed lesion , visual estimation ) arterial saphenous vein graft Lesion involve bifurcation ≥ 1.5 mm diameter ostial lesion &gt; 40 % stenosed visual estimation side branch require predilatation Excessive tortuosity proximal within lesion ( Extreme angulation ( ≥ 90 % ) proximal ) Calcification lesion Restenotic previous intervention The target vessel contain visible thrombus Chronic total occlusion ( CTO ) Another clinically significant lesion locate major epicardial vessel target lesion ( include side branch ) Patient high probability procedure predilatation stenting required time procedure treatment target vessel ( e.g . atherectomy , cut balloon ) Non clinical investigation percutaneous intervention target vessel &lt; 6 month prior plan do within 6 month investigational procedure . Non clinical investigation percutaneous intervention nontarget vessel &lt; 1 month prior investigational procedure TIMI flow = 3 evidence dissection time clinical investigation procedure , plan do within 6 month investigational procedure . General Exclusion Criteria Evidence acute MI within 3 week intend investigational procedure Patient current unstable arrhythmias Patient known leave ventricular ejection fraction ( LVEF ) &lt; 30 % Patient receive heart transplant organ transplant wait list organ transplant Patient receiving schedule receive chemotherapy malignancy within 30 day prior procedure Patient receive immunosuppression therapy know immunosuppressive autoimmune disease ( e.g . human immunodeficiency virus , systemic lupus erythematosus etc . ) Patient receive schedule receive chronic anticoagulation therapy ( e.g. , heparin , coumadin ) Patient know hypersensitivity contraindication aspirin , heparin bivalirudin , clopidogrel ticlopidine , contrast sensitivity adequately premedicated Elective surgery plan within first 6 month procedure require discontinue either aspirin clopidogrel Patient platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 , WBC &lt; 3,000 cells/mm3 , document suspect liver disease ( include laboratory evidence hepatitis ) Patient know renal insufficiency creatine clearance &lt; 40 ml/min patient dialysis Patient history bleed diathesis coagulopathy refuse blood transfusion Patient cerebro vascular accident ( CVA ) transient ischemic neurological attack ( TIA ) within past six month Patient significant GI urinary bleed within past six month Patient extensive peripheral vascular disease precludes safe 6 French sheath insertion Patient medical illness ( e.g. , cancer congestive heart failure ) know history substance abuse ( alcohol , cocaine , heroin etc . ) may cause noncompliance clinical investigation plan , confound data interpretation associate &lt; 24 month limited life expectancy Vulnerable population ( refer §6.4 ) Patient already participate another clinical investigation yet reach primary endpoint Pregnant nursing patient plan pregnancy clinical investigation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Bioresorbable</keyword>
	<keyword>Coronary</keyword>
	<keyword>Stent</keyword>
	<keyword>Vascular Remodeling</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Coronary Artery Disease</keyword>
</DOC>